Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 11/20 | 0.39 |
| ▸ | ITGAV | P06756 | 11/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.37 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.37 |
| ▸ | ITGB6 | P18564 | 4/20 | 0.37 |
| ▸ | ITGB8 | P26012 | 4/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30474583 | 1.00 | UHRF1 (0.53) | UHRF1ITGB3ITGAVCXCR4ITGB5 | |
| SCHEMBL6060377 | 0.94 | UHRF1 (0.47) | UHRF1ITGB3ITGAVCXCR4ITGB5 | |
| SCHEMBL279310 | 0.88 | UHRF1 (0.43) | UHRF1NNMT | |
| SCHEMBL18202389 | 0.77 | ITGB3 (0.39) | UHRF1ITGB3ITGAVCXCR4ITGB5 | |
| SCHEMBL21284330 | 0.77 | ITGB3 (0.41) | UHRF1ITGB3ITGAVCXCR4ITGB5 | |
| SCHEMBL1810290 | 0.77 | ITGB3 (0.39) | UHRF1ITGB3ITGAVCXCR4ITGB5 | |
| SCHEMBL8168165 | 0.77 | ITGAV (0.39) | UHRF1ITGB3ITGAVCXCR4ITGB5 | |
| SCHEMBL6322003 | 0.77 | UHRF1 (0.34) | UHRF1 | |
| SCHEMBL14419571 | 0.77 | ITGAV (0.38) | UHRF1ITGB3ITGAVCXCR4ITGB5 | |
| SCHEMBL12158643 | 0.77 | ITGB3 (0.36) | UHRF1ITGB3ITGAVCXCR4ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104402934-B | Preparation method and application of 2-(diphenylphosphineethyl)-(5,6,7,8-tetrahydroquinolinyl)amine ruthenium complexes | 河北师范大学 | 2017-01-25 | — | — | CN | claimed |
| WO-2024145245-A2 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024137502-A2 | PNU ANTHRACYCLINE-DERIVED LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024091894-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024092069-A1 | CXCR4 INHIBITORS FOR TREATMENT OF NEUROLOGICAL DISEASES | X4 PHARMACEUTICALS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024083086-A1 | BICYCLIC DERIVATIVE INTEGRIN INHIBITOR | 上海如凌生物医药有限公司 | 2024-04-25 | — | — | WO | disclosed |
| CN-117903171-A | Integrin inhibitors of a class of bicyclic derivatives | 上海如凌生物医药有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4328230-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20020081626-A1 | Methods and kits for the detection of arginine compounds | FAL DIAGNOSTICS | 2002-06-27 | — | — | US | disclosed |
| US-20020077321-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2002-06-20 | — | — | US | disclosed |
| US-20020072518-A1 | For therapy tumor metastasis, tumor growth, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelorosis, macular degeneration, retinopathy | PHARMACIA CORPORATION | 2002-06-13 | — | — | US | disclosed |
| WO-2002018377-A1 | COMPOUNDS CONTAINING A BICYCLIC RING SYSTEM USEFUL AS ALPHA V BETA 3 ANTAGONISTS | PHARMACIA CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002004465-A1 | METHODS AND KITS FOR THE DETECTION OF ARGININE COMPOUNDS | FAL DIAGNOSTICS (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001096307-A2 | CYCLOALKYL ALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001017959-A2 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-15 | — | — | WO | disclosed |
| US-4739063-A | USING CATALYST | PHILLIPS PETROLEUM COMPANY (US) | 1988-04-19 | — | — | US | disclosed |
| US-4739064-A | USING GROUP 8 METAL CATALYSTS AND REACTION MODIFIERS | PHILLIPS PETROLEUM COMPANY (US) | 1988-04-19 | — | — | US | disclosed |
| US-4160094-A | Tetrahydroquinoline derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | UHRF1 2277/4885ITGB3 4156/4885ITGAV 3874/4885 |
| US-20020072518-A1 | For therapy tumor metastasis, tumor growth, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelorosis, macular degeneration, retinopathy | ITGB1, ITGB5, ITGB3 | UHRF1 4733/4885ITGB3 3/4885ITGAV 9/4885 |
| US-20020081626-A1 | Methods and kits for the detection of arginine compounds | ARGLU1, PRMT5, PRMT3 | UHRF1 3354/4885ITGB3 4709/4885ITGAV 4605/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | UHRF1 2226/4885ITGB3 4522/4885ITGAV 4792/4885 |
| US-20020077321-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | ITGA5, ITGB5, ITGB3 | UHRF1 4827/4885ITGB3 3/4885ITGAV 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.